CLINICAL_TRIALS ClinicalTrials.gov record update

Efficacy and Safety of Allogeneic γδ T Cells (γδ T Cells) Combined With Interferon-alpha1b (IFN-α1b) or PD-1 Monoclonal Antibody in Neoadjuvant Treatment of Stage III-IV Resectable Melanoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06212388
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:20.960942+00:00
Published At: 2024-01-25T00:00:00+00:00
Record Updated At: 2024-01-25
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Melanoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-01-25"
protocolSection.identificationModule.nctId: "NCT06212388"
protocolSection.identificationModule.officialTitle: "Efficacy and Safety of Allogeneic \u03b3\u03b4 T Cells (\u03b3\u03b4 T Cells) Combined With Interferon-alpha1b (IFN-\u03b11b) or PD-1 Monoclonal Antibody in Neoadjuvant Treatment of Stage III-IV Resectable Melanoma"
protocolSection.statusModule.overallStatus: "NOT_YET_RECRUITING"
protocolSection.designModule.phases: ["EARLY_PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.